A detailed history of Morgan Stanley transactions in Bio Restorative Therapies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 17,500 shares of BRTX stock, worth $23,275. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,500
Previous 15,000 16.67%
Holding current value
$23,275
Previous $30,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.32 - $1.98 $3,300 - $4,950
2,500 Added 16.67%
17,500 $30,000
Q2 2024

Oct 17, 2024

BUY
$1.15 - $2.22 $5,750 - $11,100
5,000 Added 50.0%
15,000 $30,000
Q2 2024

Aug 14, 2024

BUY
$1.15 - $2.22 $5,750 - $11,100
5,000 Added 50.0%
15,000 $30,000
Q1 2024

Oct 17, 2024

SELL
$1.28 - $3.45 $6,400 - $17,250
-5,000 Reduced 33.33%
10,000 $13,000
Q1 2024

Aug 16, 2024

SELL
$1.28 - $3.45 $6,400 - $17,250
-5,000 Reduced 33.33%
10,000 $13,000
Q1 2024

May 15, 2024

BUY
$1.28 - $3.45 $12,800 - $34,500
10,000 New
10,000 $13,000
Q2 2022

Aug 15, 2022

SELL
$2.95 - $5.85 $73 - $146
-25 Closed
0 $0
Q1 2022

Oct 27, 2022

BUY
$3.3 - $5.69 $82 - $142
25 New
25 $0
Q1 2022

May 13, 2022

BUY
$3.3 - $5.69 $82 - $142
25 New
25 $0

Others Institutions Holding BRTX

About BioRestorative Therapies, Inc.


  • Ticker BRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 3,650,030
  • Market Cap $4.85M
  • Description
  • BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtx...
More about BRTX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.